View source for 20.109(F22):Journal article presentation

<div style="padding: 10px; width: 820px; border: 5px solid  #434a43;">
{{Template:20.109(F22)}}



==Overview and logistics== 

<font color=#0404B4>'''You will complete this assignment individually.'''</font color> <br>

Please review the 20.109 [http://engineerbiology.org/wiki/20.109(F22):Laboratory_tour#Statement_on_collaboration_and_integrity statement on collaboration and integrity] as you proceed.

In Module 1, you delivered a Research talk that was focused on your research project.  For this assignment, you will present work completed by other scientists that has been peer-reviewed and published.  Reading, understanding, and explaining research related to your project are all important skills that will be important as you flex your scientist muscles.  

As you prepare your talk be sure to review the resources provided on the [[20.109(F22):Communication| Communication tab]].  In addition, please use the following link to view the full video from Susan McConnell: [http://www.youtube.com/watch?v=Hp7Id3Yb9XQ Designing effective scientific presentations].  Lastly, review the Journal club presentation Evaluation rubric (linked [[Media:JC presentation rubric updatedSu20.pdf|here]])!

===Method of submission===

Please submit your completed Journal club slides <font color=red>'''1 hr prior to your scheduled laboratory session time'''</font color> to [https://canvas.mit.edu/courses/15914 Canvas], with filename '''Name_LabSection_JC.pptx''' (for example, ImaStudent_TR_JC.pptx).

===Length and format of presentations===

You will have 10 minutes to discuss the journal article you select.  It may be very difficult, or impossible, to discuss all of the figures within the article adequately in only 10 minutes.  Therefore, this assignment is not only to present the work, but also to identify the data that is most important to the conclusions.  It is also critical to consider how your presentation 'flows' from one experiment to the next.  As when you write your own research, you want to deliver a coherent story during your journal presentation.

====Format considerations====

The timing provided here is a guideline for a 10-minute presentation.  Your presentation may vary depending on the content. 

{|border="1"
!Section
!Minutes
!Number of slides
!DO
!DON'T
|-
!Introduction
|~2
|2-3
| 
*Introduce the key concepts that the audience will need to follow your presentation.
*Briefly state the overall scope and significance of the study -- what is the central question and why is it interesting?
*Try to summarize background material with a model slide rather than lines of text.  If text is needed, bring in the details as you speak using PowerPoint animation.
|
*Don't assume you are addressing an expert audience.
*Don't give more information than is absolutely needed to understand the rest of your talk.
*Don't put too much information on each slide. 
|-
!Data
|~7
|4-6
|
*Present the data in a logical sequence, letting each slide build upon the previous ones.
*Include a title for each slide. The title should be the conclusion and should be unique to the information on the slide.
*Make every element of your slide visible to the entire room. This means 20-point font or greater.
*Interpret each slide thoroughly and carefully.
*Point out strengths and weaknesses of the data along the way.
|
*Don't read your talk. Similarly, do not read lists from slides.
*Don't put much information on each slide. Each slide should make only one point.
*Never say, "I know you can't read this, but...". Everything on each slide should be legible.
*Don't be afraid to remind the audience how the data fits into the overall question
|-
!Summary
|~1
|1
|
*Review each of your main messages.
*Clearly state what the study contributed to the field.
|
*Don't repeat experimental details.
|-
!Question & Answer
|?
|0
|
*Answer the question being asked. If you are unclear about the question, ask for clarification.
*Respect every question and questioner.
|
*Don't take too long with one question. If the discussion is involved, suggest meeting after the talk to discuss it more.
|}

====Helpful hints====

*A 10-minute talk is NOT a 30-minute talk given while racing through slides and speaking very quickly.  
*Consider ways to '''transition from one slide to the next''' to ensure the information is tied together.
*Practice your presentation in front of people rather than in a room by yourself and '''practice several times'''!
*Familiarize yourself with using a laser pointer and/or slide changer if you will use one during the actual presentation.  
*If you do choose to use a pointer, use it to '''direct attention to specific elements''' on the screen, rather than constantly gesturing in the general vicinity of your slide; otherwise, the audience will not know what's important. When you later make your own slides and figures, the apparent need for a pointer may actually mean you need to make a clearer slide.

==Article selection==
You may choose to select a journal article from those provided by the teaching faculty or you can select an article that is related to your Module 2 research from any peer-reviewed journal.
*If you choose an article from below, please "reserve" it by putting your (initials/lab section/team color) next to the listing here. 
**For visibility, please use the following format to sign up if possible, substituting in your own initials and team color: <nowiki><font color = purple><b>[IS/WF/Purple]</b></font color></nowiki>, which will look like <font color = purple><b>[IS/WF/Purple]</b></font color>. Thanks!
*If you would like to discuss a paper not on the list below, please email it (as .pdf) to the teaching faculty (Noreen, Leslie, and Becky) with a brief description of the work.
**The list of papers below is provided as a guideline for the types of papers that might be relevant for your presentation. You are not limited to the primary research articles on this list. The list is provided simply to give you an idea of the kinds of subjects that could make suitable presentations for the class. Feel free to search [http://www.ncbi.nlm.nih.gov/pubmed PubMed] yourself to find articles of interest to you. 

'''Please review the articles before making your final selection to ensure it is a paper that you find interesting and that you are comfortable presenting!'''

===Biology of ''P. falciparum''===

#Abshire, J., ''et. al.'' "[[Media:Abshire Quantification of labile heme.pdf| Quantification of labile heme in live malaria parasites using a genetically encoded biosensor.]]" (2017) PNAS. E2068-E2076.<font color = green><b>[SS/WF/Green]</b></font color>
#Carrique, L., ''et. al.'' "[[Media:Carrique Structure and catalytic regulation...IMP.pdf|Structure and catalytic regulation of ''Plasmodium falciparum'' IMP specific nucleotidase.]]" (2020) Nat Commun. 11:3228.
#Garten, M., ''et. al.'' "[[Media:Garten EXP2 is a nutrient-permeable channel.pdf|EXP2 is a nutrient-permeable channel in the vacuolar membrane of ''Plasmodium'' and is essential for protein export via PTEX.]]" (2018) Nat Microbiol. 3:1090-1098.
#Green, J., ''et. al.'' "[[Media:Green Ubiquitin activation is essential for schizont.pdf|Ubiquitin activation is esential for schizont maturation in ''Plasmodium falciparum'' blood-stage development.]]" (2020) PLoS Pathog 16:e1008640.
#Hitz, E., ''et. al.'' "[[Media:Hitz PfMAP-2 is essential.pdf|PfMAP-2 is essential for male gametogenesis in the malaria parasite ''Plasmodium falciparum''.]]" (2020) Sci Rep. 10:11930.
#Jain, R., ''et. al.'' "[[Media:Jain Molecular dynamica...Pf14-3 and PfCDPK1.pdf|Molecular dynamics simulation and biochemical characterization of P''f''<sub>14-3-3</sub> and P''f''CDPK<sub>1</sub> interaction towards its role in growth of human malaria parasite.]]" (2020) Biochem J. 477:2153-2177. <font color = pink><b>[BG/TR/Pink]</b></font color>
#Liu, H., ''et. al.'' "[[Media:Liu Actin related protein Arp4.pdf|Actin-related protein Arp4 regulates euchromatic gene expression and development through H2A.Z deposition in blood-stage ''Plasmodium falciparum''.]]" (2020) Parasites Vectors. 13:314. 
#Llora-Batlle, O., ''et. al.'' "[[Media:Llora-Batlle Conditional expression of PFAP2-G.pdf|Conditional expression of PfAP2-G for controlled massive sexual conversion in ''Plasmodium falciparum''.]]" (2020) Sci Adv. 6:eaaz5057.<font color = blue><b>[MH/WF/Blue]</b></font color>
#Siddiqui, A., ''et. al.'' "[[Media:Siddiqui Rab7...complex assembly.pdf|Rab7 of ''Plasmodium falciparum'' is involved in its retromer complex assembly near the digestive vacuole.]]" (2020) Biochem Biophys Acta Gen Subj. 1864:129656. 
#Walszak, M., ''et. al.'' "[[Media:Walczak ATG8 is essential specifcally for an autophagy.pdf|ATG8 is essential specifically for an autophagy-independent function in apicoplast biogenesis in blood-stage malaria parasites.]]" (2018) mBio. 9:e02021-17.

===Druggable targets and drug discovery===

#Cheviet, T., ''et. al.'' "[[Media:Cheviet bHydroxy and bAminophosphonate.pdf| &beta;-Hydroxy- and &beta;-aminophosphonate acyclonucleosides as potent inhibitors of ''Plasmodium falciparum'' growth.]]" (2020) J Med Chem. Online ahead of print. 
#Colon-Lorenzo, E., ''et. al.'' "[[Media:Colon-Lorenzo Structure based screening...CB-27.pdf|Structure-based screening of ''Plasmodium berghei'' glutathione S-transferase identified CB-27 as a novel antiplasmodial compound.]]" (2020) Front Pharm. 11:246. 
#Harmsen, C., ''et. al.'' "[[Media:Harmsen Immunization with virus like particles.pdf|Immunization with virus-like particles conjugated to CIDR&alpha;1 domain of ''Plasmodium facliparum'' erythrocyte membrane protein 1 induces inhibitory antibodies.]]" (2020) Malaria J. 19:132. <font color = green><b>[EF/TR/Green]</b></font color> <font color = orange><b>[AE/WF/Yellow]</b></font orange>
#Istvan, E., ''et. al.'' "[[Media:Istvan Plasmodium Niemann-Pick type C1.pdf|''Plasmodium'' Niemann-Pick type C1-related protein is a druggable target reguired for parasite membrane homeostasis.]]" (2019) eLife. 8:e40529. <font color = purple><b>[UH/TR/Purple]</b></font color> <font color = blue><b>[NO/WF/Blue]</b></font color>
#Jain, R., ''et. al.'' "[[Media:Jain Development of anti-malarial compound.pdf|Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like CDPK1, a multistage growth regulator of ''P. falciparum''.]] (2020) Biochem J. 477:1951-1970. <font color = Pink><b>[DL/WF/Pink]</b></font color>
#LaMonte, G., ''et. al.'' "[[Media:LaMonte Pan-active imidazolopiperazine.pdf|Pan-active imidazolopiperazine antimalarials target the ''Plasmodium falciparum'' intracellular secretory pathway.]]" (2020) Nat Commun. 11:1780. 
#Nasamu, A., ''et. al.'' "[[Media:Armiyaw Plasmepsins IX and X.pdf|Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress adn invasion.]]" (2017) Science. 358:518-522. <font color = green><b>[AL/TR/Green]</b></font color>
#Polino, A., ''et. al.'' "[[Media:Polino Assessment of biological role...plasmepsin V.pdf|Assessment of biological role and insight into druggability of the ''Plasmodium falciparum'' protease plasmepsin V.]]" (2020) ACS Infect Dis. 6:738-746. 
#Sternberg, A., and Paul Roepe. "[[Media:Sternberg 4-kinase IIIb.pdf|Heterologous expression, purification, and functional analysis of the ''Plasmodium falciparum'' phosphatidylinositol 4-kinase III&beta;.]]" (2020) Biochem. 59:2494-2506.<font color = green><b>[GY/WF/Green]</b></font color>
#Vanaerschot, M., ''et. al.'' "[[Media:Vanaerschot Inhibition of resistance-refractory.pdf| Inhibition of resistance-refractory ''P. falciparum'' kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity.]]" (2020) Cell Chem Biol.  27:806-816. <font color = orange><b>[CM/WF/Yellow]</b></font color>

===Epidemiology of malaria===

#Chaves, L., ''et. al.'' "[[Media:Chaves Global consumption...malaria risk.pdf|Global consumption and international trade in deforestation-associated commodities could influence malaria risk.]]" (2020) Nat Commun. 11:1258.  <font color = pink><b>[IW/TR/Pink]</b></font color>
#Hancock, P., ''et. al.'' "[[Media:Hancock Mapping trends in insecticide.pdf|Mapping trends in insecticide resistance phenotypes in African malaria vectors.]]" (2020) PLoS Biol. 18:e3000633. <font color = purple><b>[KC/TR/Purple]</b></font color>
#Ibrahim, A., ''et. al.'' "[[Media:Ibrahim Selective whole genome amplification.pdf|Selective whole genome amplification of ''Plasmodium malariae'' DNA from clinical samples reveals insights into population structure.]] (2020) Sci Rep. 10:10832. 
#Kigozi, S., ''et. al.'' "[[Media:Kigozi Rapid shifts in age-specific burden.pdf|Rapid shifts in the age-specific burden of malaria following successful control interventions in four regions of Uganda.]]" (2020) Malaria J. 19:128.  <font color = pink><b>[JZ/WF/Pink]</b></font color> <font color = yellow><b>[CB/TR/Yellow]</b></font color>
#Lemma, Wossenseged. "[[Media:Lemma Impact of malaria incidence...male laborers.pdf| Impact of high malaria incidence in seasonal migrant and permanent adult male laborers in mechanized agricultural farms in Metema - Humera lowlands on malaria elimination program in Ethiopia.]]" (2020) BMC Pub Health. 20:320.
#Maraka, M., ''et. al.'' "[[Media:Maraka Seven year surveillance...key drivers of dispersion.pdf|A seven-year surveillance of epidemiology of malaria reveals travel and gender are the key drivers of dispersion of drug resistant genotypes in Kenya.]]" (2020) Peer J. 8:e8082. 
#Obeng-Adjei, N., ''et. al.'' "[[Media:Obeng-Adjei Longitudinal analysis of...PfEMPi.pdf|Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identified associations with malaria protection.]]" (2020) JCI Insight. 5:e137262. <font color = blue><b>[AD/TR/Blue]</b></font color>
#Verity, R., ''et. al.'' "[[Media:Verity Impact of antimalarial resistance on genetic.pdf|The impact of antimalarial resistance on the genetic structure of ''Plasmodium falciparum'' in the DRC.]]" (2020) Nat Commun. 11:2107. <font color = blue><b>[SA/TR/Blue]</b></font color>